Aerosol transmitted COVID-19 virus (SARS-CoV-2) is infectious causing both symptomatic and asymptomatic infections. The viable COVID-19 virus transmission via air has occurred. Therefore, methods must be established to determine the viability of the virus and to disinfect it in air, surfaces, and on foodstuff. In this review article, we have discussed the pattern virus spread in bus, hospital, and cruise ship. The methods of reducing and eliminating the infection in household and public places have been suggested. The safety, efficacy, and phase 3 trials data published by major vaccine candidates Russian Gamaleya’s “Sputnik V”, Oxford University –AstraZeneca, CanSino Biologics, and Moderna Therapeutics have been included. The article is very useful to stop the COVID-19 pandemic spread and finally ending the pandemic.
Shervani Z, et al. SARS-CoV-2 Delayed Tokyo 2020 Olympics: Very Recent Advances in COVID-19 Detection, Treatment, and Vaccine Development Useful Conducting the Games in 2021. Advances in Infectious Diseases. 2020; 10: 56-66.
Shervani Z, et al. COVID-19 Vaccine. Advances in Infectious Diseases. 2020;10: 195-210.
Shervani Z, et al. World’s Fastest Supercomputer Picks COVID-19 Drug. Advances in Infectious Diseases. 2020; 10: 211-225.
Guo Z, et al. Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020, Emerging Infectious Diseases. 2020; 26: 1586-1591.
Shen Y, et al. Community Outbreak Investigation of SARS-CoV-2 Transmission Among Bus Riders in Eastern China. Journal of the American Medical Association Internal Medicine. Published online, September 1, 2020.
Doremalen NV, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. The New England Journal of Medicine. 2020; 382: 1564-1567.
Jessica H, et al. Stability and Viability of SARS-CoV-2. The New England Journal of Medicine. 2020; 382: 1962-1966.
Chin AWH, et al. Stability of SARS-CoV-2 in different environmental conditions. The Lancet. 2020; 1: e10.
Chin AWH, et al. Stability of SARS-CoV-2 in different environmental conditions. Authors’ reply. The Lancet. 2020; 1: e146.
Hirose R, et al. Survival of SARS-CoV-2 and influenza virus on the human skin: Importance of hand hygiene in COVID-19. Clinical Infectious Diseases, Published on October 3, 2020.
Gandhi M, et al. Facial Masking for Covid-19 — Potential for “Variolation” as We Await a Vaccine. The New England Journal of Medicine, Published online September 8, 2020.
Logunov DY, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia, The Lancet.2020;396:887-897.
Folegatti PM, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet, 2020;396:467-478.
Zhu F, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. The Lancet, 2020;395:1845-1854.
Jackson LA, et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report, The New England Journal of Medicine, Published online July 14, 2020.
Burki TK, The Russian vaccine for COVID-19, The Lancet. 2020; 8: e85-e86.
Abbott A, RESEARCHERS QUESTION RUSSIAN COVID VACCINE TRIAL RESULTS. Nature.2020;585: 493.
Logunov DY, et al. Safety and efficacy of the Russian COVID-19 vaccine: more information needed Authors’ reply. The Lancet.2020;396: e54-e55.
This work is licensed under a Creative Commons Attribution 4.0 International License.